| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| CC5-H52P3 | Human | Human CCR5 Full Length Protein-VLP (HEK293) | |||
| CC5-H52D1 | Human | Human CCR5 Protein, Flag,His Tag |  |
|
|
Human CCR5, Flag,His Tag (Cat. No. CC5-H52D1) captured on CM5 chip via anti-His antibody can bind Anti-CCR5 antibody (Human IgG1) with an affinity constant of 0.0737 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).
Purified NA/LE Mouse Anti-Human CD195 (Clone: 2D7) (Mouse IgG2a) captured on CM5 chip via anti-mouse antibodies surface can bind Human CCR5, Flag,His Tag (Cat. No. CC5-H52D1) with an affinity constant of 7.51 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Maraviroc | MVC; UK-427857 | Approved | Viiv Healthcare | Celsentri, Selzentry | Mainland China | HIV Infections | Godecke Gmbh | 2007-08-06 | HIV Infections; Acquired Immunodeficiency Syndrome; Arthritis, Rheumatoid | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| BMS-813160 | BMS-813160 | Phase 2 Clinical | Bristol-Myers Squibb Company | Pancreatic Neoplasms; Diabetic Nephropathies; Hyperplasia; Colorectal Neoplasms | Details |
| BMS-687681 | BMS-687681 | Phase 1 Clinical | Bristol-Myers Squibb Company | Neoplasms | Details |
| SB-728-HSC | SB-728-HSC; SB-728-HSPC; SB-728mR-HSPC | Phase 1 Clinical | Sangamo Biosciences | HIV Infections | Details |
| GSK-706769 | GSK-706769 | Phase 1 Clinical | Glaxosmithkline Plc | HIV Infections; Arthritis, Rheumatoid; Autoimmune Diseases | Details |
| Thioraviroc | Phase 1 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | HIV Infections | Details | |
| Vicriviroc | SCH-D; MK-4176; SCH-417; Sch-417690 | Phase 2 Clinical | Merck & Co Inc | Acquired Immunodeficiency Syndrome; HIV Infections; Colorectal Neoplasms | Details |
| SB-728-T | SB-728-T; SB-728mR-T | Phase 2 Clinical | Sangamo Biosciences | HIV Infections | Details |
| OB-002H | OB-002; 5P12-RANTES | Phase 1 Clinical | HIV Infections | Details | |
| CAL-1-transduced hematopoietic stem cell gene therapy (Calimmune) | Cal-1 | Phase 2 Clinical | Calimmune | HIV Infections; Breast Neoplasms; Neoplasm Metastasis | Details |
| Emtricitabine/Maraviroc/Tenofovir Disoproxil Fumarate | Phase 1 Clinical | University Of Texas Medical Branch, Oak Crest Institute Of Science, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Auritec Pharmaceuticals | HIV Infections | Details | |
| Cenicriviroc mesylate/Tropifexor | LJC-242 | Phase 2 Clinical | Novartis Pharma Ag | Non-alcoholic Fatty Liver Disease | Details |
| Cenicriviroc mesylate | CVC; TAK-652; TBR-652; CCR5/CCR2 antagonist | Phase 3 Clinical | Tobira Therapeutics, Takeda Pharmaceutical Co Ltd | Prediabetic State; HIV Infections; Acquired Immunodeficiency Syndrome; Diabetes Mellitus, Type 2; Non-alcoholic Fatty Liver Disease; Liver Cirrhosis; Cholangitis, Sclerosing; Hepatic Insufficiency; Obesity; Cognition Disorders | Details |
This web search service is supported by Google Inc.
A-Z
